Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population

Hepatitis C virus (HCV) genotypes and genetic variants of interleukin 28B (IL28B) are significantly associated with interferon plus ribavirin treatment of HCV infection. We investigated the distribution of HCV genotypes and single‐nucleotide polymorphisms (SNPs) of IL28B (rs12979860 and rs8099917) i...

Full description

Saved in:
Bibliographic Details
Published in:APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2015-04, Vol.123 (4), p.342-349
Main Authors: Imran, Muhammad, Manzoor, Sobia, Azam, Sikandar, Resham, Saleha
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Female
Genetic Markers
genotypes
Hepacivirus - genetics
Hepatitis
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Humans
interferon therapy
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Male
Pakistan
Polyethylene Glycols - therapeutic use
Polymerase Chain Reaction
polymorphism
Polymorphism, Restriction Fragment Length
Polymorphism, Single Nucleotide
Recombinant Proteins - therapeutic use
responders
Ribavirin - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C virus (HCV) genotypes and genetic variants of interleukin 28B (IL28B) are significantly associated with interferon plus ribavirin treatment of HCV infection. We investigated the distribution of HCV genotypes and single‐nucleotide polymorphisms (SNPs) of IL28B (rs12979860 and rs8099917) in Pakistani population. IL28B genotyping was performed by allele‐specific PCR and restriction fragment length polymorphism PCR in 140 chronic hepatitis C patients (CHC) and 120 healthy controls. HCV genotype 3 (HCVG3) was the most prevalent genotype, 71.4% (n = 100/140) and with the highest treatment response of 90% (n = 90/100). The overall treatment response of all the HCV genotypes was 82% (n = 115/140). The distribution of IL28B rs12979860CC genotype in treatment responder and non‐responder groups was 40.8% (n = 47/115) and 16% (n = 4/25) respectively. IL28B rs12979860CC genotype demonstrated a significant correlation (p = 0.019) with interferon‐based therapy of HCV infection. However, there was no observed association of IL28B rs8099917 polymorphism with treatment response in CHC patients (p = 0.264). In conclusion, HCV genotypes and IL28B rs12979860 are predictive markers for the efficiency of interferon plus ribavirin combinational therapy of HCV infection. We recommend the inclusion of testing for these markers in the clinical criteria for decision making for HCV therapy in Pakistani population.
ISSN:0903-4641
1600-0463
DOI:10.1111/apm.12365